<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: This phase I study evaluated <z:chebi fb="0" ids="38940">sunitinib</z:chebi> plus modified FOLFOX6 (mFOLFOX6: <z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi>, leucovorin and <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>) in Japanese patients with treatment-na√Øve <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>PATIENTS AND METHODS: <z:chebi fb="0" ids="38940">Sunitinib</z:chebi> was administered orally (37.5 mg/day, 4 weeks on, 2 weeks off [Schedule 4/2; arm A] or 50 mg/day, 2 weeks on, 2 weeks off [Schedule 2/2; arm B]) with mFOLFOX6 </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: In arms A/B, respectively (n=6 each): median relative dose intensity was 50.4%/89.1% for <z:chebi fb="0" ids="38940">sunitinib</z:chebi> and 39.2-69.8%/73.0-80.5% for mFOLFOX6 components </plain></SENT>
<SENT sid="3" pm="."><plain>Most adverse events were grade 1/2 </plain></SENT>
<SENT sid="4" pm="."><plain>The most frequent grade 3/4 adverse events were <z:hpo ids='HP_0001875'>neutropenia</z:hpo>, <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo>, and <z:hpo ids='HP_0001882'>leukopenia</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>No significant drug-drug interactions were detected </plain></SENT>
<SENT sid="6" pm="."><plain>Four patients had objective responses in each arm </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSION: <z:chebi fb="0" ids="38940">Sunitinib</z:chebi> plus mFOLFOX6 had acceptable tolerability, with the Schedule 2/2 combination being generally more manageable than the Schedule 4/2 </plain></SENT>
<SENT sid="8" pm="."><plain>Based on two global trials and the present study, <z:chebi fb="0" ids="38940">sunitinib</z:chebi> on Schedule 2/2 combined with chemotherapy may be considered, if further first-line trials are planned </plain></SENT>
</text></document>